Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.

Abstract

Systemic immunoglobulin light chain (AL) amyloidosis is a disorder characterized by the production of clonal serum free light chains that misfold, aggregate, and deposit in vital organs. Treatment of this disease is typically targeted at the abnormal plasma cell clone in the bone marrow which is the source of the amyloidogenic light chain. First-line therapies in this disease are well established, but in the relapsed or refractory setting, there are many treatment options, including immunomodulatory agents, proteasome inhibitors, alkylating agents, and monoclonal antibodies. Decisions regarding treatment choice should be made by a multidisciplinary team with consideration of the patient's functional status, disease stage, degree of organ dysfunction, and potential treatment toxicities. Herein we review the current treatment options available for patients with relapsed or refractory AL amyloidosis.

• Authors: Shayna Sarosiek, Vaishali Sanchorawala
• Journal: Journal of blood medicine (J Blood Med) Vol. 10 Pg. 373-380 ( 2019) ISSN: 1179-2736 [Print] New Zealand
• PMID: 31695543 (Publication Type: Journal Article, Review)
• Copyright: © 2019 Sarosiek and Sanchorawala.